• Geron published a medical research presentation comparing imetelstat with best available therapy in relapsed or refractory myelofibrosis.
• Updated analysis showed median overall survival of 30.7 months with imetelstat versus 15.4 months in matched real-world data; hazard ratio 0.512; P=.003.
• Propensity-weighted analyses were consistent; ATO median overall survival 32.0 months versus 14.9 months; hazard ratio 0.467; P=.0019.
• Real-world outcomes improved over time; median overall survival 34.2 months for patients diagnosed after 2016 versus 15.4 months before; hazard ratio 0.492; P=.008.
• Treatment patterns shifted, with shorter time to start ruxolitinib and shorter ruxolitinib duration in patients diagnosed after 2016.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.